Navigation Links
Leukemia Drug Breakthrough Study In New England Journal Of Medicine

Alan List, M.D., leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute, recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells. The study is reported in the Feb.10 issue of the New England Journal of Medicine.

Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.

In another finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into cytogenetic remission, meaning that the chromosome abnormality disappeared.

List, a professor of interdisciplinary oncology at the University of South Florida, initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus deletion.

In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in re search and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt's sole mission is to contribute to the prevention and cure of cancer.


'"/>

Source:University Of South Florida Health Sciences Center


Related biology news :

1. Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis
2. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
3. Loosen up, DNA: Leukemia gene changes genetic packaging
4. Leukemia drug turns mini-molecules up, cancer genes down
5. Breakthrough Microarray-based Technology for the Study of Cancer
6. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
7. Breakthrough isolating embryo-quality stem cells from blood
8. Breakthrough System for Understanding Ocean Plant Life Announced
9. Breakthrough: Scientists create worlds tiniest organic particles
10. Breakthrough in micro-device fabrication combines biology and synthetic chemistry
11. Sciences Breakthrough of the Year: Watching evolution in action
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... ... therapeutics product portfolio with a near term focus on Type 2 diabetes and ... commercialization experience across multiple therapeutic areas and classes. As Chief Commercial Officer, Justin ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... ... that demonstrates the effectiveness of the Invictus Medical Neoasis™ active noise control device ... The study reported that the Neoasis™ device attenuated the alarm sounds from patient ...
(Date:7/10/2020)... ... July 08, 2020 , ... Overcoming Comparability ... Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 p.m.-3:00 p.m. EDT, ... is the most effective way to complete one? Will the study comply with ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... , ... August 29, 2020 , ... ... Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will provide ... standards and advanced technology. , “This facility will improve the flexibility of ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... firm, is making available for free its new white paper – Simulated ... simulation testing into today’s biologics licensing application (BLA). In response, Modality Solutions ...
(Date:8/3/2020)... , ... August 03, 2020 , ... Introducing Ardent Animal ... transformative growth, , Known as MediVet Biologics since its formation ... The new Ardent Animal Health will build on its base of innovative ...
(Date:7/31/2020)... ... 29, 2020 , ... Anomet Products has introduced new custom ... use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad ... performance, and cost criteria; especially where solid wire is limited. Typical configurations for ...
Breaking Biology Technology: